MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

MiNK Therapeutics (NASDAQ:INKT) released its quarterly earnings results on Thursday. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02), Zacks reports.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK advanced agenT-797 into a randomized Phase II ARDS study, with enrollment continuing in Ukraine and U.S. sites expected to begin enrolling in September. The company expects preliminary randomized data in the first half of 2027 and is preparing to discuss a potential seamless Phase III design with the FDA.
• Initial observations from two treated patients showed survival without fever at day 28, improved oxygenation, ARDS resolution, spontaneous breathing, vasopressor liberation, infection control, and no major treatment-related serious adverse events. However, management emphasized that the data are early, non-comparative, and based on a small run-in cohort.
• MiNK launched its first international paid named-patient access program in Brazil, generating physician-directed access and payments while building cross-border logistics and regulatory infrastructure. The company said additional patients were treated after quarter-end and that further financial details are expected with its third-quarter update.
• MiNK ended the quarter with $8.8 million in cash, down from $9.5 million at the end of the first quarter, while quarterly operating cash use increased to $2.1 million as the Phase II trial was operationalized. The company continues to report losses and did not provide explicit cash-runway guidance.

MiNK Therapeutics Stock Performance

INKT stock traded down $0.36 during trading on Thursday, hitting $11.00. The company had a trading volume of 8,592 shares, compared to its average volume of 9,561. The firm has a 50-day moving average price of $11.34 and a 200-day moving average price of $11.23. MiNK Therapeutics has a 12 month low of $8.48 and a 12 month high of $18.17.

Institutional Investors Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC lifted its position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,247 shares of the company’s stock after acquiring an additional 1,441 shares during the quarter. Geode Capital Management LLC owned approximately 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent reporting period. Institutional investors own 2.87% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on INKT shares. Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Zacks Research upgraded MiNK Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 14th. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of MiNK Therapeutics in a research note on Monday, May 18th. Finally, Weiss Ratings raised MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.00.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.